Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1152 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Ribociclib and Fulvestrant and PI3K Inhibitor (Buparlisib or Alpelisib) for HR Positive, HER2 Negative Postmenopausal Breast Cancer – Second or Third Line	Alpelisib (BYL719; Piqray) , Fulvestrant (Faslodex) , Ribociclib (Kisqali; LEE-011; ribociclib succinate)	Breast cancer	Breast Cancer	2017	View \| Download
Ribociclib with endocrine therapy for HR+/HER2- early breast cancer – adjuvant treatment	Endocrine therapy , Ribociclib (Kisqali; LEE-011; ribociclib succinate)	Breast cancer	Breast Cancer	2022	View \| Download
Rigosertib for myelodysplastic syndrome - second line	Rigosertib (Estybon; ON-01910.Na)	Myelodysplastic syndrome (MDS)	Haematological Cancer and Lymphomas	2020	View \| Download
Riluzole oral film formulation for amyotrophic lateral sclerosis	Riluzole	Amyotrophic lateral sclerosis	Neurology	2022	View \| Download
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia	Rilzabrutinib	Immune thrombocytopenia (ITP)	Haematology , Immunology	2023	View \| Download
Rimegepant for the treatment of Acute Migraine	Rimegepant (Zydis; BHV3000; Nurtec)	Migraine	Neurology	2018	View \| Download
Ripretinib for gastrointestinal stromal tumour	Ripretinib (DCC-2618; Quinlock)	Gastrointestinal stromal tumour (GIST)	Gastrointestinal Cancer	2021	View \| Download
Ripretinib for treating advanced gastrointestinal stromal tumours – fourth-line	Ripretinib (DCC-2618; Quinlock)	Gastrointestinal stromal tumour (GIST)	Gastrointestinal Cancer	2020	View \| Download
Risankizumab (by subcutaneous injection) for Active Psoriatic Arthritis After Inadequate Control or Intolerance to Conventional Drugs	Risankizumab (BI 655066; Skyrizi; ABBV 066)	Psoriatic arthritis	Dermatology , Rheumatology	2017	View \| Download
Risankizumab (by Subcutaneous Injection) for Moderate to Severe Chronic Plaque Psoriasis	Risankizumab (BI 655066; Skyrizi; ABBV 066)	Plaque psoriasis	Dermatology	2017	View \| Download